Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Aquestive Therapeutics, Inc. (AQST)
Last aquestive therapeutics, inc. earnings: 3/11 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.aquestive.com/investor-relations
Company Research
Source: Yahoo! Finance
Anaphylm pre-commercial activities underway; launch expected in Q1 2026, if approved by the FDA Initial Anaphylm pediatric clinical trial results in subjects 7-17 years of age in line with expectations AQST-108 (epinephrine) Topical Gel Phase 2a clinical trial on track to begin in Q2 2025 Proforma cash and cash equivalents as of December 31, 2024 approximately $93.0 million Company to host investment community conference call on March 6, 2025 WARREN, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a progress update on the key 2025 objectives previously outlined by the Company. "We are thrilled to announce today the start of our Anaphylm application pr
Show less
Read more
Impact Snapshot
Event Time:
AQST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AQST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AQST alerts
High impacting Aquestive Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AQST
News
- Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Jim Cramer on Aquestive Therapeutics: “I Think It's a Very Interesting Spec” [Yahoo! Finance]Yahoo! Finance
- Looking at the Narrative for Aquestive Therapeutics After Patent Wins and FDA Milestones [Yahoo! Finance]Yahoo! Finance
- Aquestive Therapeutics, Inc. (NASDAQ:AQST) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.10 [Yahoo! Finance]Yahoo! Finance
- Aquestive Therapeutics (NASDAQ:AQST) had its price target raised by analysts at Piper Sandler from $5.00 to $8.00. They now have an "overweight" rating on the stock.MarketBeat
AQST
Earnings
- 11/5/25 - Miss
AQST
Sec Filings
- 12/5/25 - Form 4
- 12/4/25 - Form 4
- 11/17/25 - Form 144
- AQST's page on the SEC website